

RECEIVED

MAY 8 8 2002

TECH CENTER 1600/2900

Attorney Docket No. E 1067/20037

Customer No. 03000

#1  
RECEIVED  
PATENT  
TECH CENTER 1600/2900  
MAY 20 2002  
RECEIVED  
TECH CENTER 1600/2900  
MAY 20 2002  
PH 12:55  
5/24/02  
Leg. Dist.  
a/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION

Applicants : Daniel J. O'Mahony and Michela Seveso  
Serial No. : 09/443,780  
Filed : November 19, 1999  
For : ANTIBODIES TO PEPTIDES THAT TARGET  
GIT RECEPTORS AND RELATED METHODS  
Group : 1643  
Examiner : L. Scheiner

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING DISKETTE  
(Response to Communication of April 19, 2002)

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Responsive to the Communication of April 19, 2002, Applicants are, by hand delivery on May 20, 2002, submitting this letter and a Sequence Listing diskette with a .prj file identical to the one that Applicants submitted on November 21, 2001 and March 7, 2002. The present diskette also has the .ST25.txt version of the file.

The .ST25.txt version should provide an acceptable Sequence Listing. A conversation that the undersigned had with Mark Spencer of the Patent Office on May 17,

RECEIVED  
MAY 8 8 2002  
TECH CENTER 1600/2900

2002, resulted in the undersigned's understanding that it would be sufficient if at least the .ST25.txt version was acceptable to the Patent Office. Viewing the file after opening it with Microsoft Notepad indicated that the .ST25.txt file should be acceptable.


Statements required by 37 CFR 1.821 and 1.825

The content of the paper copy (in the Amendment submitted November 21, 2001) and the attached computer readable copies of the Sequence Listing are the same and, where applicable, contain no new matter.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOW, LTD.

May 17, 2002

By   
Allan H. Fried  
Registration No. 31,253  
Seven Penn Center  
12th Floor  
1635 Market Street  
Philadelphia, PA 19103-2212  
(215) 567-2010  
Attorneys for Applicant

**RECEIVED**

MAY 23 2002

Application No.: 09/443,780**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreliable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

RECEIVED

MAY 23 2002

TECH CENTER 1600

**CRF Problem Report**

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/443,780 AFiling Date: 11/19/1999Date Processed by STIC: 3/11/2002

STIC Contact: Mark Spencer, 703-308-4212

**Nature of Problem:**

The CRF (was):

- ☐ (circle one) Damaged or Unreadable (for Unreadable, see attached)
- ☐ Blank (no files on CRF) (see attached)
- ☐ Empty file (filename present, but no bytes in file) (see attached)
- ☐ Virus-infected. Virus name: \_\_\_\_\_ The STIC will not process the CRF.
- ☐ Not saved in ASCII text
- ☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.
- ☒ Did not contain a Sequence Listing. (see attached sample)
- ☐ Other: \_\_\_\_\_

**PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.  
SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePA/EB)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

RECEIVED  
TECH CENTER 1600/2000  
02 MAY 20 PM 12:56

09/443,780 11

~~ CProject

CProjectData     DAntibodies To Peptides That Target GIT Receptors And Related  
Methods  
E1067/20037  
US 09/443,7801999-11-19

~~ CProteinSequence  
SEQ ID NO:1 Artificial SequenceITNAKHSSHNRLRTR  
15     ARNDBCQEGHILKMFPSTWYVX     PRT     CCommentFe  
ature

Random peptide  
COtherFeature

MISC\_FEATURE Linked to dansyl group 1 1     ?  
SEQ ID NO:2 Artificial  
Sequence SDNAKEPGDYVCCGNGNSTG     ARNDBCQEZGHILKMFPSTWYVX     PRT  
?

(sample submitted file)

2) Patent I software was used to create this file,  
please contact Robert Wax at 703-306-4119 or  
703-308-4216  
for assistance